Corrigendum to "Synthesis and α4β2 nicotinic affinity of unichiral 5-(2-pyrrolidinyl)oxazolidinones and 2-(2-pyrrolidinyl)benzodioxanes" [Bioorg. Med. Chem. Lett. 16 (2006) 5610-5615] (DOI:10.1016/j.bmcl.2006.08.020);Synthesis and α4β2 nicotinic affinity of unichiral 5-(2-pyrrolidinyl)oxazolidinones and 2-(2-pyrrolidinyl)benzodioxanes

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 21, 2006, Pages 5610-5615

  Pallavicini, Marco ^a   Moroni, Barbara ^a   Bolchi, Cristiano ^a   Cilia, Antonio ^c   Clementi, Francesco ^b   Fumagalli, Laura ^a   Gotti, Cecilia ^b   Meneghetti, Fiorella ^a   Riganti, Loredana ^b   Vistoli, Giulio ^a   Valoti, Ermanno ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b CNR   (Italy)

^c Recordati SpA   (Italy)

Author keywords

Affinity; Benzodioxane; Ligand; nAChR; Nicotine; Oxazolidinone

Indexed keywords

1,4 BENZODIOXAN; 2 (10 METHYLPYRROLIDIN 20 YL) 1,4 BENZODIOXANE; 5 (10 METHYLPYRROLIDIN 20 YL) 1,3 OXAZOLIDIN 2 ONE; ALPHA 2 ADRENERGIC RECEPTOR; BENZODIOXAN DERIVATIVE; EFAROXAN; IDAZOXAN; IMILOXAN; NICOTINIC AGENT; OXAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG; DIOXANE DERIVATIVE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; OXAZOLIDINONE DERIVATIVE;

ARTICLE; BINDING AFFINITY; CHEMICAL STRUCTURE; DRUG BINDING; ENANTIOMER; NONHUMAN; PHARMACOPHORE; RAT; STEREOISOMERISM; SYNTHESIS; METABOLISM; PROTEIN BINDING;

DIOXANES; OXAZOLIDINONES; PROTEIN BINDING; RECEPTORS, NICOTINIC;

EID: 33748927613     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.10.039     Document Type: Erratum

References (29)

1. Jensen A.A., Frølund B., Liljefors T., and Krogsgaard-Larsen P. J. Med. Chem. 48 (2005) 4705
2. Tønder J.E., and Olesen P.H. Curr. Med. Chem. 8 (2001) 651
3. Nicolotti O., Pellegrini-Calace M., Altomare C., Carotti A., Carrieri A., and Sanz F. Curr. Med. Chem. 9 (2002) 1
4. Mazurov A., Hauser T., and Miller C.H. Curr. Med. Chem. 13 (2006) 1567
5. Pallavicini M., Moroni B., Bolchi C., Clementi F., Fumagalli L., Gotti C., Vailati S., Valoti E., and Villa L. Bioorg. Med. Chem. Lett. 14 (2004) 5827
6. Mullen G., Napier J., Balestra M., DeCory T., Hale G., Macor J., Mack R., Loch III J., Wu E., Kover A., Verhoest P., Sampognaro A., Phillips E., Zhu Y., Murray R., Griffith R., Blosser J., Gurley D., Machulskis A., Zongrone J., Rosen A., and Gordon J. J. Med. Chem. 43 (2000) 4045
7. Tatsumi R., Fujio M., Satoh H., Katayama J., Takanashi S., Hashimoto K., and Tanaka H. J. Med. Chem. 48 (2005) 2678
8. Elliott R.L., Kopecka H., Gunn D.E., Lin N.H., Garvey D.S., Ryther K.B., Holladay M.W., Anderson D.J., and Campbell J.E. Bioorg. Med. Chem. Lett. 6 (1996) 2283
9. Elliott R.L., Ryther K.B., David J.A., Raszkiewicz J.L., Campbell J.E., Sullivan J.P., and Garvey D.S. Bioorg. Med. Chem. Lett. 5 (1995) 991
10. Walker, D. P.; Jacobsen, J. E.; Acker, B. A.; Groppi, V. E.; Piotrowski, D. W. PCT WO 03/042210, 2003.
11. Dei S., Bellucci C., Buccioni M., Ferrarono M., Gualtieri F., Guandalini L., Manetti D., Matucci R., Romanelli M.N., Scapecchi S., and Deodori E. Bioorg. Med. Chem. 11 (2003) 3153
12. Ashton W.T., Cantone C.L., Meurer L.C., Tolman R.L., Greenlee W.J., Patchett A.A., Lynch R.J., Schorn T.W., Strouse J.F., and Siegl P.K.S. J. Med. Chem. 35 (1992) 2103
13. 3, 300 MHz) δ 1.50-1.90 (m, 4H), 2.35-2.60 (m, 2H), 3.20-4.20 (m, 8H), 5.00-5.20 (m, 2H), 7.15-7.45 (m, 15H). Analytical HPLC: LiChrospher 5 μm or μPorasil 10 μm column, 98:2 dichloromethane/methanol, 2 ml/min.
14. 3, 300 MHz) δ 1.15-1.30 (m, 1H), 1.55-1.75 (m, 3H), 2.38 (s, 3H), 2.25-2.41 (m, 1H), 2.46-2.61 (m, 3H), 3.17-3.23 (m, 1H), 3.51 (d, J = 13.4 Hz, 2H), 3.72 (d, J = 13.4 Hz, 2H), 3.98 (t, 1H), 7.18-7.39 (m, 10H).
15. 2O), 3.82-3.91 (m, 1H).
16. 2: C, 56.45; H, 8.29; N, 16.46. Found: C, 56.22; H, 8.36; N, 16.35.
17. Crystallographic data of 1 were obtained using an Enraf Nonius CAD-4 diffractometer (MoKα radiation) at room temperature. The structures were solved by direct methods [Altomare, A.; C. Burla, M.; Camalli, M.; Cascarano, G.; Giacovazzo, C.; Gagliardi, A.; Polidori, G. J. Appl. Crystallogr. 1994, 27, 435.] and the refinements were carried out by full-matrix least-squares using SHELX-97 [Sheldrick, G. M.; SHELX-97, University of Göttingen, Germany]. The absolute configuration of oxazolidinone asymmetric carbon was assigned on the basis of the known chirality of the pyrrolidine asymmetric centre. CCDC-616375 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB21EZ, UK; fax: +44 1223 336 033; or deposit@ccdc.cam.ac.uk).
18. Johnson, C. K.; ORTEP 11, Report ORNL-5138, Oak Ridge National Laboratory, TN, 1976.
19. 1H NMR identical to the enantiomer.
20. +); Analytical HPLC: μPorasil 10 μm column, 70:30 n-hexane/ethyl acetate, 1 ml/min.
21. 4: C, 70.78; H, 6.24; N, 4.13. Found: C, 70.61; H, 6.31; N, 4.06.
22. 3, 300 MHz): δ 1.24 (d, J = 6.2 Hz, 6H), 1.83-1.96 (m, 1H), 2.02-2.20 (m, 3H), 3.33-3.65 (m, 2H), 3.92 (dd, J = 9.2, 12.2 Hz, 1H), 4.20-4.44 (m, 3H), 4.90 (br s, 1H), 6.76-6.90 (m, 4H). Analytical HPLC: μPorasil 10 μm column, 70:30 n-hexane/ethyl acetate, 1 ml/min.
23. 2: C, 61.06; H, 7.09; Cl, 13.86; N, 5.48. Found: C, 60.84; H, 7.01; Cl, 13.69; N, 5.43.
24. 1H NMR identical to the enantiomer.
25. Carbonelle E., Sparatore F., Canu-Boido C., Salvano C., Baldani-Guerra B., Terstappen G., Zwart R., Vijverberg H., Clementi F., and Gotti C. Eur. J. Pharmacol. 471 (2003) 85
26. Diop L., Dausse J.-P., and Meyer P. J. Neurochem. 41 (1983) 710
27. Uhlen S., Dambrova M., Nasman J., Schioth H.B., Gu Y., Wikberg-Matsson A., and Wikberg J.E. Eur. J. Pharmacol. 343 (1998) 93
28. The stereoisomers of 1 and 2 were built in their protonated form using the VEGA program (freely downloadable at www.ddl.unimi.it). Their conformational analyses were performed systematically rotating the interannular rotatable bond (yielding 360 conformers) and minimizing the obtained conformers to avoid high-energy geometries (conjugate gradients until rms = 0.01). The calculations were carried out using Quanta/CHARMm package (MSI, Burlington, MA) with the force-field CHARMm v22 and the atomic charges calculated by Gasteiger's method.
29. Abelson K.S.P., and Höglund A.U. Basic Clin. Pharmacol. Toxicol. 94 (2004) 153